These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29732995)

  • 21. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of dietary supplements in inflammatory bowel disease: a systematic review.
    Rossi RE; Whyand T; Murray CD; Hamilton MI; Conte D; Caplin ME
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1357-1364. PubMed ID: 27769076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Probiotics for inflammatory bowel disease].
    Iizuka H; Takaishi H; Hibi T
    Nihon Rinsho; 2005 May; 63(5):776-80. PubMed ID: 15881169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbes, intestinal inflammation and probiotics.
    Khan MW; Kale AA; Bere P; Vajjala S; Gounaris E; Pakanati KC
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):81-94. PubMed ID: 22149584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of probiotics in inflammatory bowel disease.
    Cain AM; Karpa KD
    Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
    Hedin C; Whelan K; Lindsay JO
    Proc Nutr Soc; 2007 Aug; 66(3):307-15. PubMed ID: 17637082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model.
    Perez Visñuk D; Savoy de Giori G; LeBlanc JG; de Moreno de LeBlanc A
    Nutrition; 2020; 79-80():110995. PubMed ID: 32977125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutrition and inflammatory bowel disease: primary or adjuvant therapy.
    Tighe MP; Cummings JR; Afzal NA
    Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):491-6. PubMed ID: 21832904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of complementary and alternative approaches to immunomodulation.
    Clarke JO; Mullin GE
    Nutr Clin Pract; 2008 Feb; 23(1):49-62. PubMed ID: 18203964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production.
    Kim MS; Byun JS; Yoon YS; Yum DY; Chung MJ; Lee JC
    Benef Microbes; 2017 Apr; 8(2):231-241. PubMed ID: 28008786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.
    Plaza-Diaz J; Gomez-Llorente C; Fontana L; Gil A
    World J Gastroenterol; 2014 Nov; 20(42):15632-49. PubMed ID: 25400447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model.
    Del Carmen S; de Moreno de LeBlanc A; Levit R; Azevedo V; Langella P; Bermúdez-Humarán LG; LeBlanc JG
    Int Immunopharmacol; 2017 Jan; 42():122-129. PubMed ID: 27912148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lactic acid bacteria as a cell factory for riboflavin production.
    Thakur K; Tomar SK; De S
    Microb Biotechnol; 2016 Jul; 9(4):441-51. PubMed ID: 26686515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials.
    Dunne C; Murphy L; Flynn S; O'Mahony L; O'Halloran S; Feeney M; Morrissey D; Thornton G; Fitzgerald G; Daly C; Kiely B; Quigley EM; O'Sullivan GC; Shanahan F; Collins JK
    Antonie Van Leeuwenhoek; 1999; 76(1-4):279-92. PubMed ID: 10532384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.
    Kanai T; Mikami Y; Hayashi A
    J Gastroenterol; 2015 Sep; 50(9):928-39. PubMed ID: 25940150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete genome sequence of Lactobacillus plantarum LZ227, a potential probiotic strain producing B-group vitamins.
    Li P; Zhou Q; Gu Q
    J Biotechnol; 2016 Sep; 234():66-70. PubMed ID: 27480344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic effect of probiotic bacteria on gastrointestinal diseases.
    Sarowska J; Choroszy-Król I; Regulska-Ilow B; Frej-Mądrzak M; Jama-Kmiecik A
    Adv Clin Exp Med; 2013; 22(5):759-66. PubMed ID: 24285463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microecology as a target for therapeutic intervention in inflammatory bowel disease.
    Guarner F
    IDrugs; 2003 Sep; 6(9):868-73. PubMed ID: 12964066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Probiotics have a limited role in the treatment of inflammatory bowel disease].
    Dieleman L; Hoentjen F
    Ned Tijdschr Geneeskd; 2012; 156(40):A5206. PubMed ID: 23031240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics in inflammatory bowel disease--therapeutic rationale and role.
    Shanahan F
    Adv Drug Deliv Rev; 2004 Apr; 56(6):809-18. PubMed ID: 15063591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.